Download Catalogue
— Product Portfolio

Mechanism. Indication. Availability. In that order.

Every product listed here is documented for clinical evaluation—not curated for aesthetics. Providers and patients get the same information: what it does, who it is for, and whether it is in stock.

Flat-lay of a pharmaceutical blister pack labeled Medifen 400 on a clean white clinical surface, controlled studio lighting, sharp product detail, no hands
Flat-lay of a pharmaceutical blister pack labeled Medifen 400 on a clean white clinical surface, controlled studio lighting, sharp product detail, no hands
Side-angle shot of a pharmaceutical bottle labeled Cardivax 10 on an organized clinical shelf, cool daylight, high contrast, no people
Side-angle shot of a pharmaceutical bottle labeled Cardivax 10 on an organized clinical shelf, cool daylight, high contrast, no people
Close-up detail of pharmaceutical capsule packaging labeled Amoxilab 500 on a flat matte surface, studio lighting, crisp label legibility, no hands
Close-up detail of pharmaceutical capsule packaging labeled Amoxilab 500 on a flat matte surface, studio lighting, crisp label legibility, no hands
/ Current Formulary

Products available now

Analgesic / Anti-inflammatory
Cardiovascular / Antihypertensive
Anti-infective / Antibiotic

Medifen 400

Cardivax 10

Amoxilab 500

COX-1/COX-2 inhibitor. Indicated for mild-to-moderate pain and inflammatory conditions. Available in 400 mg oral tablet; in stock.

Beta-lactam antibiotic. Indicated for bacterial respiratory, urinary, and skin infections. Available in 500 mg capsule; in stock.

ACE inhibitor. Indicated for hypertension and chronic heart failure management. Available in 10 mg oral tablet; in stock.

Download PDF Catalogue
• Full Product Catalogue

Every formulation. Every indication. One document.

The catalogue lists all current products with dosage forms, active ingredients, therapeutic class, and stock status. Organized by clinical category for direct procurement use.

▸ Pipeline Disclosure

Upcoming formulations — plan procurement early

These formulations are in late-stage development. Disclosed here so procurement teams can assess timelines before availability.

Coming Soon — Q3 2025
Coming Soon — Q4 2025
Coming Soon — Q1 2026

Neuropax 25

Glucofix SR

Respivex Inhaler

Selective serotonin reuptake modulator for neuropathic pain. 25 mg extended-release tablet. Phase III trials complete; regulatory review underway.

SGLT-2 inhibitor for type 2 diabetes management. Sustained-release oral formulation. Manufacturing scale-up in progress; stock expected Q4.

Long-acting bronchodilator for COPD and persistent asthma. Dry-powder inhaler format. Pre-submission review with FDA; estimated Q1 2026 availability.